Currently Novo sells the drug in plastic injector pens. Lilly launched vials nearly two years ago to offer a lower-priced version of its shot and alleviate shortages. It’s unclear what Novo will charge for vials, but the company already has been aggressively discounting its obesity drugs to compete.
Novo needs to broaden its product offerings “to really capture the ambition that we have with many millions of people suffering from obesity,” Chief ...